This post was originally published on this site The European Commission has approved Darzalex (daratumumab), in combination with Revlimid (lenalidomide) and dexamethasone, as a first-line treatment for adults with multiple myeloma who are ineligible for autologous stem cell transplant (ASCT). The decision was supported by the recent approval recommendation from the Committee for Medicinal Products for Human Use, an arm of the European…
This post was originally published on this site An advisory committee for the European Medicines Agency has recommended the conditional approval of Roche‘s Polivy (polatuzumab vedotin) in combination with MabThera (rituximab) and bendamustine (a chemotherapy) for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for a hematopoietic…
This post was originally published on this site The donor-derived, or allogeneic CAR T-cell therapy candidate UCARTCS1 has been administrated to the first patient in an ongoing Phase 1 trial for relapsed/refractory multiple myeloma. The study (NCT04142619), called MELANI-01, plans to enroll up to 18 adults whose multiple myeloma relapsed after prior treatment. It is…
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has granted conditional approval to BeiGene’s Brukinsa (zanubrutinib) as a second-line treatment for adults with mantle cell lymphoma (MCL) who have received at least one prior therapy. According to BeiGene, the medication should become available to patients in the U.S. within…
This post was originally published on this site First-line maintenance therapy with Ninlaro (ixazomib) prolongs the time without disease progression in adults with multiple myeloma not treated with an autologous stem cell transplant, meeting its primary goal, data from a Phase 3 trial show. Ninlaro is an oral proteasome inhibitor marketed by Takeda. Proteasome inhibitors block…
This post was originally published on this site The University of California, Los Angeles (UCLA) is launching a fundraising initiative to help improve treatment for advanced lung diseases, including sarcoidosis. The fundraising effort — called the Lung Health Research Accelerator Fund — aims to generate a total $20 million for the creation of a new…
This post was originally published on this site Women who require assisted reproductive technology to become mothers are not more likely to develop ovarian cancer, except for those with endometriosis, a new study suggests. The study, “Assisted reproductive technology treatment and risk of ovarian cancer—a nationwide population-based cohort study,” was published in the journal Human…
This post was originally published on this site Adding the lymphoma therapy vorinostat to Revlimid (lenalidomide) maintenance therapy may deepen responses to stem cell transplants and prolong survival outcomes in multiple myeloma patients, long-term results of a Phase 1 clinical trial show. Results were published in the journal Biology of Blood and Marrow Transplantation in…
This post was originally published on this site The U.S. Food and Drug Administration has granted fast track designation to a combination of Viracta Therapeutics‘ investigational therapy nanatinostat and the antiviral valganciclovir in treating relapsed or refractory lymphomas positive for Epstein-Barr virus (EBV) infection. A therapy candidate is put on a fast track by the…
This post was originally published on this site Immune responses triggered by the investigational cancer vaccine VBI-1901 correlate with the stabilization of tumor size in patients with recurrent glioblastoma (GBM), a common and aggressive brain cancer, according to new results from a Phase 1/2a clinical trial. The latest data from part A of the trial…
